

## Ovarian Damage During Chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility

Wendy Marder<sup>1</sup>, Senait Fisseha<sup>2</sup>, Martha A. Ganser<sup>1</sup> and Emily C. Somers<sup>1-3</sup>

<sup>1</sup>Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA. <sup>2</sup>Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Michigan, Ann Arbor, Michigan, USA. <sup>3</sup>Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, MI, USA. Corresponding author email: [wmarder@umich.edu](mailto:wmarder@umich.edu)

---

**Abstract:** Women with autoimmune diseases such as lupus, scleroderma, and vasculitis receiving cyclophosphamide for severe disease manifestations risk primary ovarian insufficiency (POI) due to gonadotoxicity of this therapy. In addition to loss of reproductive potential, POI is associated with increased risk of morbidity and mortality. Practitioners caring for women requiring gonadotoxic therapies should be familiar with long-term health implications of POI and strategies for ovarian preservation. Accumulating evidence supports the effectiveness of adjunctive gonadotropin releasing hormone analog (GnRH-a) for ovarian protection during gonadotoxic therapy in cancer and autoimmune populations. GnRH-a is less costly and invasive than assisted reproductive technologies used for achievement of future pregnancies, but is not Food and Drug Administration approved for ovarian preservation. This review focuses on POI comorbidities and strategies for mitigation of related sequelae, which can accumulate over decades of hypoestrogenism. These issues are arguably more pronounced for women with chronic autoimmune diseases, in whom superimposed POI further heightens risks of cardiovascular disease and osteoporosis. Therefore, even if future pregnancy is not desired, ovarian protection during gonadotoxic therapy should be a major goal of disease management.

**Keywords:** primary ovarian insufficiency, autoimmune diseases, cyclophosphamide, fertility preservation

---

*Clinical Medicine Insights: Reproductive Health* 2012:6 9–18

doi: [10.4137/CMRH.S10415](https://doi.org/10.4137/CMRH.S10415)

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.



## Introduction

Severe manifestations of autoimmune diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis, and vasculitis, often require treatment with gonadotoxic immunosuppressive medications, particularly cyclophosphamide (CYC). While CYC administration prolongs survival in these diseases, it is associated with significant toxicity, including an unacceptably high incidence of primary ovarian insufficiency (POI) in female patients, with consequent irreversible amenorrhea and infertility.<sup>1–3</sup> Beyond reproductive implications, POI is associated with broad and long lasting detrimental effects on general health, quality of life, and life expectancy.<sup>4–6</sup> With autoimmune diseases often affecting women during their reproductive years,<sup>7</sup> it is imperative that the risks of prolonged hypoestrogenemia associated with gonadotoxic therapies are adequately recognized when formulating treatment plans. These issues have been rigorously addressed in the field of oncology, as is evidenced by the development of practice guidelines for fertility preservation in the cancer population.<sup>8</sup> In comparison, rheumatologists have yet to develop similar practice guidelines for fertility preservation in rheumatic disease patients undergoing treatment with gonadotoxic chemotherapy.

In this broad overview, we aim to: (a) increase awareness and understanding of potential health consequences, beyond infertility, of gonadotoxic therapies in young women; and (b) highlight potential strategies for mitigation of such risks and resulting comorbidities, including methods for ovarian protection.

## Triple Threat of Primary Ovarian Insufficiency, Underlying Autoimmune Disease, and Treatment Side Effects

Menopause before the age of 40 years is considered to be premature.<sup>5</sup> The term “primary ovarian insufficiency,” rather than “primary ovarian failure” or “premature menopause,” is the currently preferred term, as it is less stigmatizing and allows the condition to be viewed as a continuum of impaired ovarian function as opposed to a dichotomous state.<sup>9–11</sup> POI has become recognized as “a serious and incurable chronic disease,” the diagnosis of which requires a woman to be less than 40 years old, have experienced amenorrhea for 4 months or more, and she has to have two serum follicle stimulating hormone levels obtained at

least 1 month apart in the menopausal range.<sup>5</sup> Unlike natural menopause, which occurs on average at age 50 years,<sup>12</sup> 50% of women with POI still have variations in ovarian function, and 5%–10% conceive and deliver a child after receiving the diagnosis.<sup>5,13,14</sup>

While sequelae apply to all causes of POI (which is most frequently considered to be idiopathic, affecting 1% of women under the age of 40 years),<sup>15,16</sup> symptoms are compounded in women with autoimmune diseases. Both the underlying autoimmune/inflammatory processes and their treatments (eg, corticosteroids) are associated with many serious long-term consequences of hypoestrogenism, most notably cardiovascular disease and loss of bone mineral density.<sup>17–21</sup> These potential long-term consequences of ovarian damage, beyond infertility, may be overlooked in women with autoimmune diseases requiring CYC (often on an urgent or semi-urgent basis), and particularly among patients who may not be concerned with future childbearing.

## Medications used in Autoimmune Diseases Associated with POI and Common Sequelae

### Alkylating agents

Alkylating agents such as CYC and chlorambucil are immunosuppressive medications used to treat severe manifestations of autoimmune diseases, including SLE, systemic sclerosis, and vasculitis, and they are used as part of chemotherapeutic regimens for both hematologic malignancies and solid tumors. Even as potentially less toxic alternatives for CYC therapy become more widely applied (eg, mycophenolate mofetil),<sup>22,23</sup> CYC is still indicated in patients with organ-threatening manifestations of severe autoimmune disease. In humans, CYC-induced ovarian damage is generally regarded as cumulative and irreversible, due in part to the progressive reduction of a limited number of primordial follicles.<sup>1–3</sup> Among female patients treated with CYC for rheumatic disease or malignancy, POI develops in 12% to 83%, depending on variables including patient age, mode of administration, and cumulative CYC dose, all of which are strong predictors of POI.<sup>2,3,24–27</sup> CYC may also contribute directly to bone loss, even beyond its potential to induce a hypoestrogenic state.<sup>28,29</sup> In animal models, CYC decreases the number of osteoclasts and osteoblasts on bone surfaces, and exerts adverse effects on epiphyseal growth plates.<sup>30,31</sup>



## Glucocorticoids

Large cumulative doses of glucocorticoid therapy (GC), either by intravenous bolus dosing or through prolonged daily oral therapy, have been associated with side effects including accelerated atherosclerosis and osteoporosis.<sup>20,21,32–35</sup> Although glucocorticoid therapy is a cornerstone of treatment for patients with autoimmune diseases, efforts are continually being made to decrease cumulative exposure by maintaining patients on immunosuppressive “steroid-sparing” agents such as methotrexate, azathioprine, and mycophenolate mofetil. At high intravenous doses (eg, >250 mg), the most common immediate side effects of glucocorticoid therapy include elevation of diastolic blood pressure, cardiac arrhythmia, hyperglycemia, and flushing.<sup>36</sup> Long-term, moderate daily doses of prednisone, defined as >7.5 mg to 30 mg a day for more than 2–3 months are associated with a range of adverse outcomes, including myopathy, glaucoma, cataracts, infections, avascular necrosis, weight gain, and various mood disturbances including depression, anxiety, and even psychosis.<sup>37–39</sup> Even at low daily doses (less than 7.5 mg/day), side effects of glucocorticoids such as acne, easy bruising, weight gain, and cataracts are seen in patients who are treated for more than 90 days,<sup>40–43</sup> although the actual frequency of adverse events at low doses is not as well characterized as that associated with higher dose therapy.<sup>38</sup> Physicians caring for patients treated with glucocorticoids at any dose must be aware of these risks, many of which are compounded in patients with POI. In particular, patients with POI may be at risk for decreased bone density if they lose estrogen during their twenties and thirties, when spinal bone mineral density (BMD) increases significantly, peaking in the mid-thirties.<sup>44</sup> (Rodin et al 1990) Exposure to medications that deplete BMD and induce a hypoestrogenic state prior to or during these years may prevent young women from reaching a normal BMD.

## Comorbidities Associated with POI

### All-cause mortality

All-cause mortality has been shown to increase two-fold with early menopause.<sup>45</sup> Large observational studies of women who experience idiopathic menopause at an age of less than 50 years have revealed significantly increased age-adjusted risk of death compared to women experiencing natural menopause

at an age greater than 50 years.<sup>44,46</sup> Similarly, mortality has been shown to be significantly higher in women who undergo oophorectomy before age 45 versus referent women.<sup>47</sup> Recently, prospective data from a large, homogenous population-based study evaluating the risk of fracture and mortality associated with age at menopause revealed that at 34 years of follow-up, women undergoing menopause before age 47 had increased risks of mortality, fragility fractures, and osteoporosis at age 77.<sup>48</sup>

### Cardiovascular disease

POI of any cause may also be associated with increased morbidity and mortality from cardiovascular disease (CVD) due to premature loss of the protective effects of estrogen.<sup>45,46</sup> Data from several large cohort studies confirm the presence of a heightened CVD risk among women who had a bilateral oophorectomy before age 40 compared to after age 45, and the effect of exogenous estrogen was not necessarily protective.<sup>49,50</sup> The Mayo Clinic Cohort Study of Oophorectomy and Aging, which included over 2,000 cases of unilateral or bilateral oophorectomy compared to over 2,300 referent women who did not undergo oophorectomy, found increased mortality from CVD associated with bilateral oophorectomy if patients were not treated with HT until or past the age of 45 (HR 1.84, 95% CI 1.27–2.68).<sup>51</sup> Large scale epidemiologic studies of women with POI demonstrate CVD occurring at higher rates and at younger ages in women with POI than in control women, although not all results reached statistical significance.<sup>45,52–57</sup> For example, Snowden et al<sup>4</sup> found an increased risk of death, though this did not reach statistical significance, from coronary heart disease (adjusted OR 1.59, 95% CI 0.58–4.40) and stroke (adjusted OR 1.87, 95% CI 0.51–6.92) in women experiencing natural menopause at an age younger than 40 years as compared to those experiencing menopause at older than 50 years.

### Bone density

Osteoporosis is associated with hypoestrogenism due to ovarian insufficiency or natural menopause.<sup>58</sup> Both the time since the onset of menopause and increased chronological age are associated with lower bone density,<sup>59</sup> underscoring the well-recognized risk to bone health that accumulates over decades after early menopause.<sup>58,60,61</sup> In a population-based prospective



study of Swedish women that were followed from the age of 48 years onwards, the authors reported that by age 77, a significantly higher proportion of women who had undergone early menopause had osteoporosis (BMD by dual energy X-ray absorptiometry of hip and lumbar spine) compared to women with late or natural menopause (56% versus 30%, respectively,  $P = 0.01$ ).<sup>48</sup> Other cross sectional studies support the findings of significantly lower BMD in women undergoing oophorectomy prior to menopause as compared to women undergoing natural menopause.<sup>62,63</sup> Osteoporotic fracture rates before the age of 70 are also significantly higher among women with early menopause.<sup>64–67</sup> This problem is compounded in women with autoimmune diseases who experience early menopause, as they have underlying risks for osteoporosis not only due to chronic steroid use, but due to proinflammatory cytokines that drive their underlying inflammatory disease.<sup>33,68–71</sup> Furthermore, women with SLE have further increased risk factors for low bone density, as they often have low vitamin D levels, which are associated with sun avoidance (related to photosensitivity) and with periods of active lupus disease activity.<sup>72–74</sup>

## Mental health and neurocognition

The distress associated with POI differs from that experienced by women with natural menopause, which may be due, in part, to the abrupt and unexpected nature of the diagnosis.<sup>75–77</sup> In a study of 100 women with idiopathic POI, 84% of women felt both unprepared emotionally for their diagnosis, and that the diagnosis had created moderate to severe suffering in their lives.<sup>75</sup> Beyond the initial stress of the POI diagnosis, many studies have documented increased rates of anxiety, depression, somatization, negative affect, hostility, or sensitivity among women with POI.<sup>76,78–80</sup> A number of studies have also examined the effects of POI on a woman's sense of self, and have found a significant association with POI and lowered self-esteem, as well as with a feeling of loss of femininity.<sup>76,81–84</sup>

Neurocognitive deficits in women with POI have also been reported, including higher rates of cognitive impairment, dementia, and Parkinson's disease in women with oophorectomy when compared with controls.<sup>85–87</sup> Some of these conditions may have a cumulative effect in women with autoimmune

diseases such as SLE, for example, in whom preexisting rates of depression and cognitive dysfunction are increased compared with healthy controls.<sup>88,89</sup> These associations were stronger for those undergoing oophorectomy at a younger age, supporting the hypothesis that estrogen may have a protective effect against the neurodegenerative processes associated with natural aging.

## Quality of Life

### Vasomotor and sexual dysfunction

Classic symptoms of natural menopause such as hot flashes and night sweats are also prevalent among women with POI, and can be more severe in women who experience menopause at a younger age.<sup>87</sup> In a report by Mar Fan,<sup>90</sup> 51.4% of 41 women with chemotherapy-induced POI experienced moderate to severe hot flashes, as compared with only 19.3% of 57 women undergoing natural menopause, at 1-year follow-up. Besides the immediate discomfort, these episodes of vasomotor instability can disturb sleep and interrupt daily life, leading to impaired mood and frustration.<sup>91</sup> These symptoms represent the most common reason that women request treatment with HRT, which effectively relieves hot flashes for a majority of patients.

Studies have consistently shown that women with POI experience greater rates of sexual dysfunction than control women of comparable ages. Vaginal dryness and associated dyspareunia are commonly reported symptoms of sexual dysfunction among women with idiopathic POI, oophorectomy, chemotherapy-induced POI, and diminished ovarian reserve.<sup>16,78,92–95</sup> These symptoms can lead to a variety of related problems such as difficulty with sexual arousal, satisfaction, and difficulty reaching orgasm, often translating into emotional distress and impaired intimacy, or avoidance of sexual contact.<sup>16,75</sup>

### Interpersonal relationships

Sexual dysfunction can affect the experience of a woman's partner as well, and some data suggests that it could lead to sexual impairment in males.<sup>81</sup> In cases where a woman's partner may be desiring children, the loss of fertility may also place an added burden on the relationship.<sup>97</sup> The experience of menopause at a young age has also been described as creating a disconnect between a young woman and her peers,



making her feel older and less able to relate to mates of similar ages.<sup>91</sup>

When POI occurs in the context of chronic illness, it is difficult to assess the impact of ovarian function alone on quality of life. The studies assessed in this review represent a variety of populations and control groups, yet the consistency of results across the studies of POI suggests that it significantly impacts quality of life regardless of underlying health and prognosis. Short versus long-term effects of POI may also confound quality of life assessments. Symptoms in idiopathic POI that impact quality of life may begin months before amenorrhea or the actual diagnosis of menopause, making it difficult to accurately assess women's perceptions of the effects of POI. Some quality of life outcomes may also capture short-term consequences that may not last more than a few months after the onset of menopause. Therefore, the overall impact of POI on the perception of quality of life may be confounded by the duration of symptoms.

## Mitigation of Ovarian Damage after Cyclophosphamide

### Alternatives to use of bolus CYC

In an effort to reduce exposure to CYC, several newer therapeutic options have been investigated for the treatment of severe manifestations of autoimmune diseases. The use of CYC as induction therapy for lupus nephritis (LN) is declining since the introduction of induction therapy with mycophenolate mofetil (MMF), which may be an adequate initial therapy for mild LN, is well-tolerated,<sup>23,97</sup> and is not associated with gonadotoxicity. A subset of LN patients may also respond to the “Euro-lupus” regimen, consisting of six doses of 500 mg CYC given every 2 weeks, followed by azathioprine.<sup>98</sup> The resulting total CYC exposure of 3 grams is much lower than cumulative doses given in standard 6-month courses for LN. However, patients with severe proliferative LN with renal insufficiency, and those who do not respond initially to MMF, will still require standard monthly intravenous CYC therapy. Similarly, use of the anti-CD20 monoclonal antibody, rituximab, may be an effective alternative to CYC in some patients with systemic vasculitis,<sup>99</sup> further expanding treatment options beyond cyclophosphamide for patients with autoimmune diseases.

## Ovarian protection

A number of assisted reproductive technologies exist (eg, oocyte, embryo, or ovarian tissue cryopreservation), which may increase the chances of future childbearing for women undergoing gonadotoxic therapy; however, these “high-tech” reproductive strategies do not address the preservation of ovarian function and its attendant health benefits, which can be extremely costly, and usually requires a delay in medical treatment.

Adjunctive oral contraceptive use during gonadotoxic therapy has been proposed for the preservation of ovarian function, but convincing evidence regarding its efficacy for this purpose is lacking.<sup>100</sup> However, the accumulating data from our group and others suggest that adjunctive treatment with gonadotropin releasing hormone analog (GnRH-a) during CYC therapy protects against the loss of the ovarian reserve, as measured by gradations in anti-Mullerian hormone, a biomarker of the ovarian reserve.<sup>101</sup> Currently, we are conducting an National Institutes of Health-sponsored multicenter randomized controlled trial of GnRH-a for ovarian protection in women with autoimmune diseases receiving CYC, in order to more definitively assess the efficacy of the GnRH-a regimen in this patient population. GnRH-a therapy is far less costly and invasive than other potential methods for fertility preservation. If confirmed as efficacious, the health benefits beyond fertility preservation would make this an important adjunctive therapy to consider regardless of childbearing intentions. If the efficacy of GnRH-a is not confirmed in randomized controlled trials, future interventions should be developed with the preservation of ovarian function as a primary therapeutic strategy.

## Management of POI in Women with Rheumatic Diseases

In 2012, the North American Menopause Society addressed the issue of hormone therapy (HT) for women with POI in a position statement on the use of HT in post-menopausal women.<sup>102</sup> The authors advised that in general, women who experience premature menopause—because of their increased risk of osteoporosis, possible increased CVD risk, and their more intense hypoestrogenemic symptoms—should take HT until at least the median age of menopause. While the authors acknowledged that no comparative



data exist, they state that potential benefits for women with POI may outweigh the risks associated with taking HT. Furthermore, the risks associated with POI may actually be fewer than those incurred by older women who commence HT at or beyond the median age of menopause; specifically, the heightened risks of cardiovascular events and breast cancer have been observed among post-menopausal women treated with HT as part of the Women's Health Initiative.<sup>103</sup> Results from the Women's Health Initiative, however, do not necessarily apply to the population of women with POI, who would receive HT as a replacement until the age of natural menopause, and not as supplementary therapy past the age when the body stops naturally producing gonadal hormones. However, HT is contraindicated in patients with increased thrombotic risk, including women with antiphospholipid antibodies either as a primary syndrome, or secondary to autoimmune diseases such as SLE. Hypercoagulability has also been documented in patients with granulomatosis with polyangiitis (formerly Wegener's).<sup>104</sup> Therefore, the best strategy to try to prevent the loss of naturally occurring gonadal hormones, as the best levels recommended for replacement and even the method of delivery of HT for patients with POI have not been well established.

Although few, the currently existing randomized controlled trials that address HT recommendations for women with POI have compared physiological sex steroid replacement versus standard HT (oral ethinylestradiol and norethisterone), and found that those women treated with the physiologic replacement had improved markers of CVD, including lower blood pressure, improved renal function, and less activation of the renin-angiotensin system, as well as improvement in markers of bone mineral density in the lumbar spine.<sup>105,106</sup> However, these studies focused on proxies of disease, and it remains unclear if this treatment simply replaces estrogen until the presumed natural menopause affords young women the same health benefits as the experience of premenopausal women. Even if personalized HT treatment strategies with favorable risk-benefit profiles are developed for women with POI, poor compliance with decades of HT is frequently observed. In one study, only 48% of women with POI were taking HT, with 85% citing increased risk of cancer,

stroke, and heart attack as concerns regarding long-term HT.<sup>107</sup>

## Conclusions

It has been our experience that long-term health consequences beyond the preservation of fertility (eg, the ability to conceive a child either in vitro or in vivo), including issues of psychosocial and sexual health related to POI are often overlooked in the rheumatic disease patient population. This may be due to the sense of urgency in treating the severe active disease, or to lack of awareness on the part of the practitioner. When faced with the decision to use CYC in premenopausal patients, the burden of disease resulting from POI beyond the loss of fertility must be considered, as it confers on our patients another chronic condition that must be managed in the context of their underlying autoimmune disease. With survival rates among patients with autoimmune diseases and many malignancies improving over time,<sup>108,109</sup> attention to long-term health and quality of life for patients facing gonadotoxic therapy during their reproductive years must be incorporated into their health care plan as early as possible. A broad focus on ovarian protection and related women's health issues, rather than a focus on fertility preservation as the singular goal, is the paradigm shift we have tried to emphasize in this review by describing the wide variety of deleterious outcomes beyond the loss of fertility that are associated with POI due to any cause.

Options for fertility preservation that also prevent POI (for example, the use of GnRH-a during CYC therapy) are increasingly advocated for use in rheumatic and some oncologic diseases.<sup>101,110-117</sup> Promising results in women with SLE treated with GnRH-a during CYC make this therapy attractive, and give GnRH-a a clear advantage over vastly more expensive, invasive, and inconvenient therapies such as cryopreservation of embryos or ovarian tissue. The extensive comorbidities associated with POI discussed in this article, compounded by poor compliance with HT, as well as contraindications for HT among patients with hypercoagulability, make prevention of POI the most attractive strategy. If ovarian protection can be achieved with simple, adjunctive GnRH-a therapy, prevention of POI-



related comorbidities over time would be clearly cost-effective, which is in contrast to assisted reproductive technologies, which are costly, labor intensive, and focus solely on fertility without addressing gonadal protection and long-term health issues associated with hypoestrogenism. We and others feel that GnRH-a has the best likelihood (among currently available options) of preventing POI in our patient population receiving CYC, and we have published our protocol detailing timing and dosing during CYC therapy.<sup>116</sup> However, in advance of results from ongoing clinical trials, such use of GnRH-a is considered “off label.” Clearly, increased awareness of the health risks associated with POI is needed. Research efforts should continue to focus on prevention and mitigation of the chronic and complex sequelae of POI in this patient population.

### Author Contributions

WM, MG wrote the first draft of the manuscript: WM, MG, SF, ECS Contributed to the writing of the manuscript. WM, MG, SF, ECS agree with manuscript results and conclusions. WM, SF, ECS jointly developed the structure and arguments for the paper. WM, SF, ECS made critical revisions and approved final version. All authors reviewed and approved of the final manuscript.

### Funding

Supported by 5R01HD066139-03 from NIH/NICHD, UL1RR024986 from NIH/NICHD, and the University of Michigan Institute for Research on Women and Gender. WM was supported by K12HD001438 from NIH/ORWH.

### Competing Interests

Author(s) disclose no potential conflicts of interest.

### Disclosures and Ethics

As a requirement of publication author(s) have provided to the publisher signed confirmation of compliance with legal and ethical obligations including but not limited to the following: authorship and contributorship, conflicts of interest, privacy and confidentiality and (where applicable) protection of human and animal research subjects. The authors have read and confirmed their agreement with the

ICMJE authorship and conflict of interest criteria. The authors have also confirmed that this article is unique and not under consideration or published in any other publication, and that they have permission from rights holders to reproduce any copyrighted material. Any disclosures are made in this section. The external blind peer reviewers report no conflicts of interest.

### References

1. Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. *N Engl J Med*. 1973;289(22):159–162.
2. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. *Lupus*. 2000;9(6):401–5.
3. Boumpas DT, Austin HA 3rd, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. *Ann Intern Med*. 1993;119(5):366–9.
4. Snowden DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? *Am J Public Health*. 1989;79(6):709–14.
5. Nelson LM. Clinical practice. Primary ovarian insufficiency. *N Engl J Med*. 2009;360(6):606–14.
6. De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. *Lancet*. 2010;376(9744):911–21.
7. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. *J Autoimmun*. 2010;33(3–4):197–207.
8. Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. *J Clin Oncol*. 2006;24(22):3576–82.
9. Kalantaridou SN, Nelson LM. Premature ovarian failure is not premature menopause. *Ann N Y Acad Sci*. 2000;900:393–402.
10. Kodaman PH. Early menopause: primary ovarian insufficiency and surgical menopause. *Semin Reprod Med*. 2010;28(5):360–9.
11. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. *Clin Endocrinol (Oxf)*. 2008;68(4):499–509.
12. van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. *Fertil Steril*. 1997;68(1):95–102.
13. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. *Fertil Steril*. 1990;53(5):804–10.
14. van Kasteren YM, Schoemaker J. Premature ovarian failure: A systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. *Hum Reprod Update*. 1999;5(5):483–92.
15. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. *Obstet Gynecol*. 1986;67(4):604–6.
16. Maclaran K, Horner E, Panay N. Premature ovarian failure: long-term sequelae. *Menopause Int*. 2010;16(1):38–41.
17. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis*. 2012;71(9):1524–9.
18. García-Carrasco M, Mendoza-Pinto C, Escárcega RO, et al. Osteoporosis in patients with systemic lupus erythematosus. *Isr Med Assoc J*. 2009;11(8):486–91.
19. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. *Am J Epidemiol*. 1997;145(5):408–15.
20. Strohmayer EA, Krakoff LR. Glucocorticoids and cardiovascular risk factors. *Endocrinol Metab Clin North Am*. 2011;40(2):409–17, ix.



21. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. *2002;13(10):777–87.*
22. McCune WJ, Riskalla MM. Mycophenolate mofetil: a magic bullet for lupus? *J Rheumatol.* 2005;32(6):967–70.
23. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Engl J Med.* 2005;353(21):2219–28.
24. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. *Arthritis Rheum.* 1998;41(5):831–7.
25. Park MC, Park YB, Jung SY, Chung IH, Choi KH, Lee SK. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. *Lupus.* 2004;13(8):569–74.
26. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. *Ann Rheum Dis.* 1996;55(4):224–9.
27. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. *J Rheumatol.* 2002;29(10):2129–35.
28. Xian CJ, Cool JC, van Gangelen J, Foster BK, Howart GS. Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats. *Cancer Biol Ther.* 2007;6(2):170–7.
29. Wang TM, Shih C. Study of histomorphometric changes of the mandibular condyles in neonatal and juvenile rats after administration of cyclophosphamide. *Acta Anat (Basel).* 127(2):93–9.
30. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. *J Clin Oncol.* 2000;18(7):1570–93.
31. Zilberman O, Närsman M, Forsberg CM, Sven L. Effects of cyclophosphamide on the femoral epiphyseal growth plate in young Sprague-Dawley rats. *Acta Odontol Scand.* 2002;60(4):208–12.
32. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med.* 2004;141(10):764–70.
33. Saag KG. Glucocorticoid-induced osteoporosis. *Endocrinol Metab Clin North Am.* 2003;32(1):135–57.
34. Ruyssen-Witrand A, Fautrel B, Saraux A, Le Loët X, Pham T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. *Joint Bone Spine.* 2011;78(1):23–30.
35. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. *Curr Opin Rheumatol.* 2008;20(2):131–7.
36. Smits NA, Duru N, Bijlsma JW, Jacobs JW. Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis. *Clin Exp Rheumatol.* 2011;29(5 Suppl 68):S85–92.
37. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. *Curr Opin Ophthalmol.* 2000;11(6):478–83.
38. Hwang YG, Saag K. The safety of low-dose glucocorticoids in rheumatic diseases. *Clin Exp Rheumatol.* 2011;29(5 Suppl 68):S104–12.
39. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. *Joint Bone Spine.* 2011;78(1):41–4.
40. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. *Mayo Clin Proc.* 2006;81(10):1361–7.
41. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. *Otolaryngol Clin North Am.* 2010;43(4):753–68.
42. Fardet L, Kassab A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. *Drug Saf.* 2007;30(10):861–81.
43. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Rheum.* 2006;55(3):420–6.
44. Rodin A, Murby B, Smith MA, Caleffi M et al. Premenopausal bone loss in the lumbar spine and neck of femur: a study of 225 Caucasian women. *Bone.* 1990;11(1):1–5.
45. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. *Am J Epidemiol.* 2003;157(10):923–9.
46. Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. *Am J Epidemiol.* 2005;162(11):1089–97.
47. Parker WH, Jacoby V, Shoupe D, Rocca W. Effect of bilateral oophorectomy on women's long-term health. *Womens Health (Lond Engl).* 2009;5(5):565–76.
48. Svejme O, Ahlberg HG, Nilsson JA, Karlsson MK. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. *BJOG.* 2012;119(7):810–6.
49. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. *N Engl J Med.* 1989;321(10):641–6.
50. Knauff EA, Westerveld HE, Goverde AJ, et al. Lipid profile of women with premature ovarian failure. *Menopause.* 2008;15(5):919–23.
51. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. *Menopause.* 2009;16(1):15–23.
52. Cooper GS, Baird DD, Weinberg CR, Ephross SA, Sandler DP. Age at menopause and childbearing patterns in relation to mortality. *Am J Epidemiol.* 2000;151(6):620–3.
53. Cooper GS, Sandler DP. Age at natural menopause and mortality. *Ann Epidemiol.* 1998;8(4):229–35.
54. Gold EB, Bromberger J, Crawford S. Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol.* 2001;153(9):865–74.
55. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. *Arch Intern Med.* 1999;159(10):1061–6.
56. Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. *Maturitas.* 2006;53(2):226–33.
57. Wellons M. Cardiovascular disease and primary ovarian insufficiency. *Semin Reprod Med.* 2011;29(4):328–41.
58. Uygur D, Sengül O, Bayar D, Erdinç S, Batioğlu S, Mollamahmutoglu L. Bone loss in young women with premature ovarian failure. *Arch Gynecol Obstet.* 2005;273(1):17–9.
59. Hadjidakis D, Kokkinakis E, Sfakianakis M, Raptis SA. The type and time of menopause as decisive factors for bone mass changes. *Eur J Clin Invest.* 1999;29(10):877–85.
60. Pouillès JM, Trémollières F, Bonneau M, Ribot C. Influence of early age at menopause on vertebral bone mass. *J Bone Miner Res.* 1994;9(3):311–5.
61. Gallagher JC. Effect of early menopause on bone mineral density and fractures. *Menopause.* 2007;14(3 Pt 2):567–71.
62. Gambacciani M, Spinetti A, de Simone L, et al. The relative contributions of menopause and aging to postmenopausal vertebral osteopenia. *J Clin Endocrinol Metab.* 1993;77(5):1148–51.
63. Aitken JM, Hart DM, Anderson JB, Lindsay R, Smith DA, Speirs CF. Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. 1973;2(5862):325–8.
64. van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. *J Bone Miner Res.* 2004;19(7):1172–80.
65. Johansson C, Mellström D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. *Maturitas.* 1996;24(1–2):97–106.
66. Vega EM, Egea MA, Mautalen CA. Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. *Maturitas.* 1994;19(2):117–24.
67. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. *Osteoporos Int.* 2003;14(6):525–30.
68. Braun T, Zwerina J. Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. *Arthritis Res Ther.* 2011;13(4):235.
69. Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. *Arthritis Care Res (Hoboken).* 2012;64(1):2–8.
70. Gough AK, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. *Lancet.* 1994;344(8914):23–7.





71. Ramsey-Goldman R, Dunn JE, Huang CF, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. *Arthritis Rheum.* 1999;42(5):882–90.
72. Amital H, Szekanez Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? *Ann Rheum Dis.* 2010;69(6):1155–7.
73. Ben-Zvi I, Aranow C, Mackay M, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. *PLoS One.* 2010;5(2):e9193.
74. Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. *Osteoporos Int.* 2009;20(3):427–33.
75. Groff AA, Covington SN, Halverson LR, et al. Assessing the emotional needs of women with spontaneous premature ovarian failure. *Fertil Steril.* 2005;83(6):1734–41.
76. Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. *J Psychosom Obstet Gynaecol.* 2000;21(3):167–74.
77. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. *Hum Reprod Update.* 1999;5(5):483–92.
78. van der Stege JG, Groen H, van Zadelhoff SJ, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. *Menopause.* 2008;15(1):23–31.
79. Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. *Psychooncology.* 2001;10(3):231–41.
80. Davis M, Ventura JL, Wieners M, et al. The psychosocial transition associated with spontaneous 46,XX primary ovarian insufficiency: illness uncertainty, stigma, goal flexibility, and purpose in life as factors in emotional health. *Fertil Steril.* 2010;93(7):2321–9.
81. Graziottin A. Menopause and sexuality: key issues in premature menopause and beyond. *Ann N Y Acad Sci.* 2010;1205:254–61.
82. Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. *J Clin Psychiatry.* 2012;73(7):993–1001.
83. Orshan SA, Ventura JL, Covington SN, Vanderhoof VH, Troendle JF, Nelson LM. Women with spontaneous 46,XX primary ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. *Fertil Steril.* 2009;92(2):688–93.
84. Schmidt PJ, Cardoso GM, Ross JL, Hag N, Rubinov DR, Bondy CA. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure. *JAMA.* 2006;295(12):1374–6.
85. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. *Neurology.* 2008;70(3):200–9.
86. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. *Neurology.* 2007;69(11):1074–83.
87. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. *Gynecol Oncol.* 2009;112(3):594–600.
88. Kozora E, Arciniegas DB, Filley CM, et al. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. *Arthritis Rheum.* 2008;59(11):1639–46.
89. Bachen EA, Chesney MA, Criswell LA. Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. *Arthritis Rheum.* 2009;61(6):822–9.
90. Mar Fan HG, Houédé-Tchen N, Chemerynsky I, et al. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. *Ann Oncol.* 2010;21(5):983–7.
91. Pal L, Bevilacqua K, Zeitlian G, Shu J, Santoro N. Implications of diminished ovarian reserve (DOR) extend well beyond reproductive concerns. *Menopause.* 2008;15(6):1086–94.
92. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. *Fam Cancer.* 2001;1(3–4):149–56.
93. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. *Drug Safety.* 2005;28(5):401–16.
94. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. *Maturitas.* 2010;65(2):161–6.
95. Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. *J Clin Oncol.* 2008;26(5):753–8.
96. Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. *Menopause.* 2004;11(6 Pt 2):766–77.
97. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. *J Rheumatol.* 2003;30(7):1508–12.
98. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum.* 2002;46(8):2121–31.
99. Stone JH, Merkel PA, Spiera R, et al; for the RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-Associated Vasculitis. *N Engl J Med.* 2010;363(3):221–32.
100. Longhi A, Pignotti E, Versari M, Asta S, Bacci G. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. *Oncol Rep.* 2003;10(1):151–5.
101. Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. *Gynecol Endocrinol.* 2012;28(8):624–7.
102. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause.* 2012;19(3):257–71.
103. Rossouw JE, Anderson GL, Prentice RL, et al; for Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. *JAMA.* 2002;288(3):321–33.
104. Merkel PA, Lo GH, Holbrook JT, et al; for Wegener’s Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. *Ann Intern Med.* 2005;142(8):620–6.
105. Langrish JP, Mills NL, Bath LE, et al; Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension.* 2009;53(5):805–11.
106. Crofton PM, Evans N, Bath LE, et al. Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. *Clin Endocrinol (Oxf).* 2010;73(6):707–14.
107. Absolom K, Eiser C, Turner L, et al; for Late Effects Group Sheffield. Ovarian failure following cancer treatment: current management and quality of life. *Hum Reprod.* 2008;23(11):2506–12.
108. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin.* 2012;62(4):220–41.
109. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. *Autoimmun Rev.* 2004;3(6):423–53.
110. Blumenfeld Z, Mischari O, Schultz N, Boulman N, Balbir-Gurman A. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. *Semin Arthritis Rheum.* 2011;41(3):346–52.
111. Blumenfeld Z, Patel B, Leiba R, Zuckerman T. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation. *Fertil Steril.* Aug 27, 2012. [Epub ahead of print.]



112. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. *J Womens Health (Larchmt)*. 2009;18(3):311–9.
113. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. *Cochrane Database Syst Rev*. 2011;11 CD008018.
114. Behringer K, Thielen I, Mueller H, et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. *Ann Oncol*. 2012;23(7):1818–25.
115. Henes M, Henes JC, Neunhoeffer E, et al. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. *Lupus*. 2012;21(9): 953–8.
116. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. *Arthritis Rheum*. 2006;52(9):2761–7.
117. Somers EC, Christman GM, Fisseha S, Marder W, McCune WJ. Response to “Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.” *Oncologist*. 2008;13(5):613–4; author reply 615–7.